Efficacy and Safety of erLotinib (Tarceva® ) Therapy in patiEnts With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) , Subtype adEnocarcinoma, Who Have Good performaNce sTatus (PS 0-1) - ELEMENT
Observational
Observational Model: Cohort, Time Perspective: Prospective
Progression-free survival
approximately 2.5 years
No
Clinical Trials
Study Director
Hoffmann-La Roche
Serbia: Agency for Medicines and Medical Devices of Serbia
ML28282
NCT01836133
May 2013
February 2015
Name | Location |
---|